344 related articles for article (PubMed ID: 36013381)
1. Up-Date on Diabetic Nephropathy.
Pelle MC; Provenzano M; Busutti M; Porcu CV; Zaffina I; Stanga L; Arturi F
Life (Basel); 2022 Aug; 12(8):. PubMed ID: 36013381
[TBL] [Abstract][Full Text] [Related]
2. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Wish JB; Pergola P
Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Advances in Diabetic Nephropathy.
Sawaf H; Thomas G; Taliercio JJ; Nakhoul G; Vachharajani TJ; Mehdi A
J Clin Med; 2022 Jan; 11(2):. PubMed ID: 35054076
[TBL] [Abstract][Full Text] [Related]
4. A Narrative Review of New Treatment Options for Diabetic Nephropathy.
Pillai A; Fulmali D
Cureus; 2023 Jan; 15(1):e33235. PubMed ID: 36733548
[TBL] [Abstract][Full Text] [Related]
5. Update on diagnosis, pathophysiology, and management of diabetic kidney disease.
Sugahara M; Pak WLW; Tanaka T; Tang SCW; Nangaku M
Nephrology (Carlton); 2021 Jun; 26(6):491-500. PubMed ID: 33550672
[TBL] [Abstract][Full Text] [Related]
6. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment.
Samsu N
Biomed Res Int; 2021; 2021():1497449. PubMed ID: 34307650
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and Management of Diabetic Nephropathy in Western Countries.
Satirapoj B; Adler SG
Kidney Dis (Basel); 2015 May; 1(1):61-70. PubMed ID: 27536666
[TBL] [Abstract][Full Text] [Related]
8. Update of pathophysiology and management of diabetic kidney disease.
Lin YC; Chang YH; Yang SY; Wu KD; Chu TS
J Formos Med Assoc; 2018 Aug; 117(8):662-675. PubMed ID: 29486908
[TBL] [Abstract][Full Text] [Related]
9. Diabetic Kidney Disease.
Bonner R; Albajrami O; Hudspeth J; Upadhyay A
Prim Care; 2020 Dec; 47(4):645-659. PubMed ID: 33121634
[TBL] [Abstract][Full Text] [Related]
10. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.
Warren AM; Knudsen ST; Cooper ME
Expert Opin Ther Targets; 2019 Jul; 23(7):579-591. PubMed ID: 31154867
[No Abstract] [Full Text] [Related]
11. The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes.
García-Carro C; Vergara A; Agraz I; Jacobs-Cachá C; Espinel E; Seron D; Soler MJ
J Clin Med; 2019 Jun; 8(6):. PubMed ID: 31212945
[TBL] [Abstract][Full Text] [Related]
12. Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.
Karalliedde J; Winocour P; Chowdhury TA; De P; Frankel AH; Montero RM; Pokrajac A; Banerjee D; Dasgupta I; Fogarty D; Sharif A; Wahba M; Mark PB; Zac-Varghese S; Patel DC; Bain SC
Diabet Med; 2022 Apr; 39(4):e14769. PubMed ID: 35080257
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
14. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
Kim DL; Lee SE; Kim NH
Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
Tang G; Li S; Zhang C; Chen H; Wang N; Feng Y
Acta Pharm Sin B; 2021 Sep; 11(9):2749-2767. PubMed ID: 34589395
[TBL] [Abstract][Full Text] [Related]
16. [DIABETIC NEPHROPATHY AS A CAUSE OF CHRONIC KIDNEY DISEASE].
Kos I; Prkačin I
Acta Med Croatica; 2014 Dec; 68(4-5):375-81. PubMed ID: 26285470
[TBL] [Abstract][Full Text] [Related]
17. Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.
Johnson SA; Spurney RF
Am J Physiol Renal Physiol; 2015 Nov; 309(10):F807-20. PubMed ID: 26336162
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological Management of Diabetic Nephropathy.
Papademetriou V; Alataki S; Stavropoulos K; Papadopoulos C; Bakogiannis K; Tsioufis K
Curr Vasc Pharmacol; 2020; 18(2):139-147. PubMed ID: 30961500
[TBL] [Abstract][Full Text] [Related]
19. GLP-1 Receptor Agonists and Kidney Protection.
Greco EV; Russo G; Giandalia A; Viazzi F; Pontremoli R; De Cosmo S
Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159279
[TBL] [Abstract][Full Text] [Related]
20. Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
Fernandez-Fernandez B; Fernandez-Prado R; Górriz JL; Martinez-Castelao A; Navarro-González JF; Porrini E; Soler MJ; Ortiz A
Clin Kidney J; 2019 Jun; 12(3):313-321. PubMed ID: 31198532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
